We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Long-term relapse-free survival enabled by integrating targeted antibacteria in antitumor treatment.
- Authors
Wang, Yuanlin; Han, Yaqian; Yang, Chenhui; Bai, Tiancheng; Zhang, Chenggang; Wang, Zhaotong; Sun, Ye; Hu, Ying; Besenbacher, Flemming; Chen, Chunying; Yu, Miao
- Abstract
The role of tumor-resident intracellular microbiota (TRIM) in carcinogenesis has sparked enormous interest. Nevertheless, the impact of TRIM-targeted antibacteria on tumor inhibition and immune regulation in the tumor microenvironment (TME) remains unexplored. Herein, we report long-term relapse-free survival by coordinating antibacteria with antitumor treatment, addressing the aggravated immunosuppression and tumor overgrowth induced by TRIM using breast and prostate cancer models. Combining Ag+ release with a Fenton-like reaction and photothermal conversion, simultaneous bacteria killing and multimodal antitumor therapy are enabled by a single agent. Free of immune-stimulating drugs, the agent restores antitumor immune surveillance and activates immunological responses. Secondary inoculation and distal tumor analysis confirm lasting immunological memory and systemic immune responses. A relapse-free survival of >700 days is achieved. This work unravels the crucial role of TRIM-targeted antibacteria in tumor inhibition and unlocks an unconventional route for immune regulation in TME and a complete cure for cancer. Tumor-resident intracellular microbiota (TRIM) could be a potential target for anticancer treatment. Here the authors report Au@Ag2Se nano-assemblies enabling bacterial killing, tumor inhibition and immune regulation in tumor microenvironment.
- Subjects
IMMUNOLOGIC memory; PHOTOTHERMAL conversion; TUMOR microenvironment; COMBINED modality therapy; PROSTATE cancer
- Publication
Nature Communications, 2024, Vol 15, Issue 1, p1
- ISSN
2041-1723
- Publication type
Article
- DOI
10.1038/s41467-024-48662-x